Search PubMed⌕ Search

Biomedical subjects

G Dotevall

Publications and source records attributed to G Dotevall.

At least 55 records · Page 3Linked to original sources
PubMed1979

Inhibition of gastric acid secretion by pirenzepine (LS 519) in man.

Pirenzepine is a new tricyclic drug used in the treatment of peptic ulcer disease. The effect of two doses of pirenzepine (25 mg twice daily and 50 mg thrice daily) was examined in ten healthy volunteers during basal acid secretion and under stimulation with two doses of pentagastrin (0.166 microgram/kg . h and 1 microgram/kg.h given as continuous intravenous infusion). Serum drug concentrations were determined by radioimmunoassay, and parallel studies of the salivary function were performed. Pirenzepine, 25 mg twice daily, reduced basal acid output by 50% and 55%, respectively, and inhibited stimulated acid output by 31% and 26%, respectively. The higher dose of pirenzepine, 50 mg thrice daily, augmented the effect insignificantly despite markedly increased serum drug levels. The recommended therapeutic dose of 25 mg twice daily gave no salivary inhibition. Pirenzepine may have an anticholinergic effect on the parietal cell, although systemic side effects were not seen. Pirenzepine does not competitively inhibit pentagastrin-stimulated acid secretion.

Adult↗
PubMed1979

The effect of pirenzepine on basal, pentagastrin- and insulin-stimulated gastric acid secretion in patients with peptic ulcer disease.

The effect of pirenzepine on basal and stimulated acid secretion was tested in five patients with peptic ulcer disease and gastric hypersecretion. Two types of stimulation were compared, namely pentagastrin by intravenous infusion (1 microgram/kg/h) and hypoglycaemia induced by insulin given subcutaneously (0.125 IU/kg). Basal acid output/30 min was reduced by 44% and 69%, respectively. Pentagastrin-stimulated acid output was reduced by 30%/120 min, and insulin-stimulated acid output by 47%. The reduction was similar during the first and second hour of stimulation in both series. These results strengthen our previous impression that pirenzepine may interfere with cholinergic receptors at the parietal cell level. As the inhibition of gastric acid secretion by pirenzepine is similar to that produced by oral doses of cimetidine, pirenzepine may be useful in the treatment of peptic ulcer disease.

Adult↗
PubMed1979

Pharmacological and clinical aspects of some drugs used in peptic ulcer treatment.

A healing effect of carbenoxolone and colloidal bismuth on gastric and duodenal ulcer has been demonstrated in several studies. The use of carbenoxolone is limited by the high frequency of side effects. Information on the ability of these drugs to prevent ulcer recurrences is sparse. Further studies are needed to determine the ulcer-healing effect of deglycyrrhizinised liquorice. Sulpiride, a dopamine-blocking agent, seems to have interesting inhibitory effects on gastric secretion but its anti-ulcer activity is not yet clear.

Anti-Ulcer Agents↗
PubMed1978

[Long term effect of ipratropium bromide on gastric secretion].

In a randomised clinical trial in 10 patients, the effects of a new anticholinergic, 8-isopropyl-3 alpha-DL-tropoyloxy-1 alpha H, 5 alpha H-tropanium hydroxide (ipratropiumbromide, active principle of Atrovent), on pentagastrin-stimulated gastric secretion was investigated. The study was performed in comparison to placebo, using the double-blind technique. Each patient served as his/her own control. As earlier test results seemed to indicate that ipratropium bromide had a particularly long duration of action, the special aim of the trial was to clarify whether an oral dose of 30 mg of the product inhibits gastric secretion for more than 11 h after administration. The findings show that basal acid secretion (BAO) was significantly reduced 11 ts following placebo. On the other hand, upon determination of maximum acid secretion (MAO) 12--13 h following administration, there was no difference between the anticholinergic and placebo. The results of the study of the study are discussed.

Atropine Derivatives↗
PubMed1978

Diagnostic value of hypotonic duodenography in superior mesenteric artery syndrome.

The superior mesenteric artery syndrome is a compression of the duodenum. We believe that the diagnostic limitations of the routine barium meal studies can be abolished by hypotonic duodenography. Before surgical treatment other pathological conditions should be excluded. Peptic ulcer disease often coexists. Patients with persisting signs and symptoms after surgery for ulcer should be re-examined with this condition in mind. The adequate treatment is duodenojejunostomy.

Adult↗
PubMed1976

The absorption of acetylsalicylic acid from the stomach in relation to intragastric pH.

A comparative study on the effect of a buffered (pH 6.5) and an unbuffered (pH 2.9) solution of acetylsalicylic acid (ASA) on gastric pH, gastric emptying, and gastric absorption of ASA was performed in 10 healthy volunteers. Gastric pH was recorded using radiotelemetry. Gastric emptying and gastric absorption was studied with an aspiration technique and phenol red as nonabsorbable marker. Administration of the unbuffered solution to the fasting subjects resulted in a gastric pH of about 2 and absorption of ASA from the stomach was found to occur. The buffered solution of ASA increased gastric pH to above 5 and gastric absorption of ASA was found to be significantly less than after the unbuffered solution. The buffered solution was emptied from the stomach more rapidly than the unbuffered one.

Administration, Oral↗
PubMed1974

Controlled clinical trial of mepiprazole in irritable bowel syndrome.

The effect of a new tranquillizer, mepiprazole, in the treatment of the irritable bowel syndrome has been studied in a double-blind cross-over trial in 19 patients. After examination to exclude organic disease the patients were followed up over two treatment periods of four weeks each under either placebo or the active principle, each patient being his own control. The results indicated that the drug had a beneficial effect (P < 0.05) provided that it was given for a period of at least three weeks.

Adult↗